[go: up one dir, main page]

MX2019003069A - Uso de pridopidina para tratar el sindrome de rett. - Google Patents

Uso de pridopidina para tratar el sindrome de rett.

Info

Publication number
MX2019003069A
MX2019003069A MX2019003069A MX2019003069A MX2019003069A MX 2019003069 A MX2019003069 A MX 2019003069A MX 2019003069 A MX2019003069 A MX 2019003069A MX 2019003069 A MX2019003069 A MX 2019003069A MX 2019003069 A MX2019003069 A MX 2019003069A
Authority
MX
Mexico
Prior art keywords
pridopidine
rett syndrome
treating rett
subject
treating
Prior art date
Application number
MX2019003069A
Other languages
English (en)
Inventor
Geva Michal
Laufer Ralph
Hayden Michael
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of MX2019003069A publication Critical patent/MX2019003069A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar a un sujeto afectado por el síndrome de Rett que comprende administrar al sujeto una cantidad efectiva de pridopidina para tratar así al sujeto.
MX2019003069A 2016-09-16 2017-09-15 Uso de pridopidina para tratar el sindrome de rett. MX2019003069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
MX2019003069A true MX2019003069A (es) 2019-09-02

Family

ID=61619744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003069A MX2019003069A (es) 2016-09-16 2017-09-15 Uso de pridopidina para tratar el sindrome de rett.

Country Status (13)

Country Link
EP (2) EP4005570B1 (es)
JP (1) JP6977029B2 (es)
CN (1) CN109982686A (es)
AU (1) AU2017326013B2 (es)
BR (1) BR112019005040A2 (es)
CA (1) CA3036984C (es)
DK (2) DK3512506T3 (es)
ES (2) ES2909557T3 (es)
HU (1) HUE058314T2 (es)
IL (1) IL265342B2 (es)
MX (1) MX2019003069A (es)
PL (2) PL3512506T3 (es)
WO (1) WO2018053280A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
AU2017315783C1 (en) 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
KR101319235B1 (ko) 2004-10-13 2013-10-16 아이백스 인터내셔널 게엠베하 4-(3-메탄설폰일페닐)-1-n-프로필-피페리딘의 합성 공정
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
KR102479759B1 (ko) 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja) * 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom

Also Published As

Publication number Publication date
EP3512506B1 (en) 2022-01-26
AU2017326013A1 (en) 2019-04-11
DK3512506T3 (da) 2022-04-19
HUE058314T2 (hu) 2022-07-28
PL3512506T3 (pl) 2022-05-30
JP2019532926A (ja) 2019-11-14
PL4005570T3 (pl) 2024-09-23
DK4005570T3 (da) 2024-08-19
JP6977029B2 (ja) 2021-12-08
WO2018053280A1 (en) 2018-03-22
CN109982686A (zh) 2019-07-05
ES2909557T3 (es) 2022-05-09
CA3036984A1 (en) 2018-03-22
EP4005570A1 (en) 2022-06-01
CA3036984C (en) 2023-07-18
ES2986807T3 (es) 2024-11-12
BR112019005040A2 (pt) 2019-07-16
EP3512506A4 (en) 2020-05-27
EP4005570B1 (en) 2024-05-15
EP3512506A1 (en) 2019-07-24
IL265342B2 (en) 2023-06-01
IL265342A (en) 2019-05-30
AU2017326013B2 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2019002190A (es) Uso de pridopidina para tratar distonías.
PH12015502075B1 (en) Treatment of cataplexy
GB2541571A (en) Pharmaceutical compositions
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
NZ722600A (en) Methods of treating mild brain injury
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
UA90546U (uk) Спосіб лікування хворих на дисциркуляторну енцефалопатію
UA103888U (uk) Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому